Brain tumor trial aims to boost radiation without boosting harm

NCT ID NCT05871021

Recruiting now Disease control Sponsor: University Hospital Tuebingen Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether giving a higher dose of radiation along with a drug called bevacizumab can help people with a fast-growing brain tumor (glioblastoma) live longer. About 146 adults aged 18 to 70 with a specific type of glioblastoma will receive the treatment. The goal is to improve survival without causing more side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glioblastoma IDH-wildtype glioblastoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLIOBLASTOMA

Contacts and locations

Locations

Department of Neurology, University Hospital Regensburg
RECRUITING

Regensburg, Germany
Department of Radiation Oncology
RECRUITING

Tübingen, 72076, Germany
Department of Radiation Oncology, Medical Faculty Mannheim
RECRUITING

Mannheim, Germany
Department of Radiation Oncology, University Hospital Augsburg
RECRUITING

Augsburg, Germany
Department of Radiation Oncology, University Hospital Frankfurt
RECRUITING

Frankfurt, Germany
Department of Radiation Oncology, University Hospital Freiburg
RECRUITING

Freiburg im Breisgau, Germany
Department of Radiation Oncology, University Hospital Köln
RECRUITING

Cologne, Germany
Department of Radiation Oncology, University Hospital Leipzig
RECRUITING

Leipzig, Germany
Department of Radiation Oncology, University Hospital, LMU Munich
RECRUITING

Munich, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.